The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Case report: the continued efficacy of low-dose ibrutinib for CLL after 10 years of treatment
In this video, Inga Mandac-Smoljanovic, MD, PhD, Merkur Clinical Hospital, Zagreb, Croatia, presents a case report of a 52-year-old male patient with chronic lymphocytic leukemia (CLL) who has been on ibrutinib treatment for 10 years. The patient was started on 140 mg of the agent in 2014 and continues to receive this dose over a decade later. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So that was a 52-year-old male patient who has been diagnosed with CLL in 2005. So at that time point we didn’t have many options, but in the next three years he progressed and started treatment with fludarabine and cyclophosphamide, which did put some improvement on him, but after three years we had to repeat the treatment but added rituximab. For some years he was okay, but in 2015 he really progressed with a high CLL burden, very symptomatic disease...
So that was a 52-year-old male patient who has been diagnosed with CLL in 2005. So at that time point we didn’t have many options, but in the next three years he progressed and started treatment with fludarabine and cyclophosphamide, which did put some improvement on him, but after three years we had to repeat the treatment but added rituximab. For some years he was okay, but in 2015 he really progressed with a high CLL burden, very symptomatic disease. And at that time point, we knew that in 2014 ibrutinib was approved, but we didn’t have it still in Croatia. So we applied for the patient for ibrutinib compassionate use. At that time point, he had a positive serology for hepatitis B infection, and as we knew the Resonance study excluded these patients, but we were pretty desperate, as well as the patient, and we started ibrutinib in a reduced dose of 140 mg daily. Ten years after, the patient is great and still continues with 140 mg and with antiviral prophylaxis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
